Protalix Biotherapeutics Stock Price, News & Analysis (NYSEAMERICAN:PLX)

$0.67 0.01 (1.52 %)
(As of 11/18/2017 05:09 AM ET)
Previous Close$0.67
Today's Range$0.66 - $0.69
52-Week Range$0.26 - $1.51
Volume596,524 shs
Average Volume1.83 million shs
Market Capitalization$333.79 million
P/E RatioN/A
Dividend YieldN/A

About Protalix Biotherapeutics (NYSEAMERICAN:PLX)

Protalix Biotherapeutics logoProtalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase II clinical trials to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.

Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Sector: Biotechnology & Medical Research - NEC
  • Previous Symbol: NYSEMKT:PLX
  • CUSIP: N/A
  • Web:
  • Outstanding Shares: 139,730,000

Frequently Asked Questions for Protalix Biotherapeutics (NYSEAMERICAN:PLX)

What is Protalix Biotherapeutics' stock symbol?

Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."

How were Protalix Biotherapeutics' earnings last quarter?

Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) posted its earnings results on Wednesday, November, 8th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.04. The firm had revenue of $7.53 million for the quarter, compared to analysts' expectations of $6.65 million. During the same period last year, the firm earned ($0.07) EPS. View Protalix Biotherapeutics' Earnings History.

Where is Protalix Biotherapeutics' stock going? Where will Protalix Biotherapeutics' stock price be in 2017?

3 brokerages have issued 12 month target prices for Protalix Biotherapeutics' stock. Their predictions range from $1.00 to $5.00. On average, they expect Protalix Biotherapeutics' share price to reach $3.67 in the next twelve months. View Analyst Ratings for Protalix Biotherapeutics.

Are investors shorting Protalix Biotherapeutics?

Protalix Biotherapeutics saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 6,749,650 shares, an increase of 1.6% from the October 13th total of 6,642,728 shares. Based on an average daily volume of 3,511,610 shares, the days-to-cover ratio is presently 1.9 days. Approximately 5.5% of the company's shares are short sold.

Who are some of Protalix Biotherapeutics' key competitors?

Who are Protalix Biotherapeutics' key executives?

Protalix Biotherapeutics' management team includes the folowing people:

  • Shlomo Yanai, Chairman of the Board (Age 64)
  • Moshe Manor, President, Chief Executive Officer, Director (Age 60)
  • Yossi Maimon CPA, Chief Financial Officer, Vice President, Treasurer, Secretary (Age 46)
  • Tzvi Palash, Chief Operating Officer (Age 60)
  • Yoseph Shaaltiel Ph.D., Executive Vice President - Research & Development (Age 63)
  • Einat Brill Almon Ph.D., Senior Vice President - Product Development (Age 57)
  • Amos Bar-Shalev, Independent Director (Age 64)
  • Zeev Bronfeld, Independent Director (Age 66)
  • Yodfat Harel Buchris, Independent Director (Age 45)
  • Roger D. Kornberg Ph.D., Independent Director (Age 69)

How do I buy Protalix Biotherapeutics stock?

Shares of Protalix Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Protalix Biotherapeutics' stock price today?

One share of Protalix Biotherapeutics stock can currently be purchased for approximately $0.67.

How big of a company is Protalix Biotherapeutics?

Protalix Biotherapeutics has a market capitalization of $333.79 million.

How can I contact Protalix Biotherapeutics?

Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.

MarketBeat Community Rating for Protalix Biotherapeutics (NYSEAMERICAN PLX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  28 (Vote Outperform)
Underperform Votes:  26 (Vote Underperform)
Total Votes:  54
MarketBeat's community ratings are surveys of what our community members think about Protalix Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Protalix Biotherapeutics (NYSEAMERICAN:PLX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.67

Consensus Price Target History for Protalix Biotherapeutics (NYSEAMERICAN:PLX)

Price Target History for Protalix Biotherapeutics (NYSEAMERICAN:PLX)

Analysts' Ratings History for Protalix Biotherapeutics (NYSEAMERICAN:PLX)

DateFirmActionRatingPrice TargetDetails
11/9/2017HC WainwrightReiterated RatingBuy$5.00View Rating Details
5/23/2017Rodman & RenshawReiterated RatingBuy$5.00View Rating Details
12/15/2016MackieReiterated RatingBuy$1.00View Rating Details
9/6/2016Jefferies Group LLCLower Price TargetBuy$1.75 -> $0.80View Rating Details
(Data available from 11/19/2015 forward)


Earnings History and Estimates Chart for Protalix Biotherapeutics (NYSEAMERICAN:PLX)

Earnings by Quarter for Protalix Biotherapeutics (NYSEAMERICAN:PLX)

Earnings History by Quarter for Protalix Biotherapeutics (NYSEAMERICAN PLX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 17($0.05)($0.09)$6.65 million$7.53 millionViewN/AView Earnings Details
8/9/20176/30/2017($0.04)($0.06)$5.05 million$6.36 millionViewListenView Earnings Details
5/10/2017Q1 17($0.09)($0.07)$2.55 million$2.89 millionViewN/AView Earnings Details
8/8/2016Q2 16($0.08)($0.11)$1.34 million$1.77 millionViewN/AView Earnings Details
3/8/2016Q415($0.29)$3.50 million$4.40 millionViewN/AView Earnings Details
11/9/2015Q3 15($0.08)($0.04)$5.00 million$4.30 millionViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.05)$6.40 million$3.78 millionViewN/AView Earnings Details
5/7/2015Q1 15($0.08)($0.06)$8.20 million$4.39 millionViewN/AView Earnings Details
8/7/2014($0.07)($0.07)$9.63 million$2.43 millionViewN/AView Earnings Details
5/8/2014($0.07)($0.08)$8.25 million$6.70 millionViewN/AView Earnings Details
3/13/2014Q413($0.02)($0.12)$5.54 million$2.36 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Protalix Biotherapeutics (NYSEAMERICAN:PLX)

No earnings estimates for this company have been tracked by


Dividend History for Protalix Biotherapeutics (NYSEAMERICAN:PLX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Protalix Biotherapeutics (NYSEAMERICAN PLX)

Insider Trades by Quarter for Protalix Biotherapeutics (NYSEAMERICAN:PLX)
Institutional Ownership by Quarter for Protalix Biotherapeutics (NYSEAMERICAN:PLX)

Insider Trades by Quarter for Protalix Biotherapeutics (NYSEAMERICAN PLX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/1/2017Steve DabnerDirectorBuy6,000$0.32$1,920.00
8/31/2017Steve DabnerDirectorBuy10,000$0.33$3,300.00
7/28/2017Steve DabnerDirectorBuy500$0.36$180.00
7/26/2017Steve DabnerDirectorBuy3,500$0.35$1,225.00
7/25/2017Steve DabnerDirectorBuy10,000$0.35$3,500.00
6/2/2017Randall Peel BoydInsiderBuy38,300$0.47$18,001.00
5/16/2017Moshe ManorCEOBuy50,000$0.81$40,500.00View SEC Filing  
1/27/2017Terence Stanley MeekDirectorBuy12,000$0.42$5,040.00
1/25/2017Madalena Energy Inc.InsiderSell190,500$0.38$72,390.00
1/23/2017Madalena Energy Inc.InsiderSell500$0.39$195.00
1/12/2017Madalena Energy Inc.InsiderSell54,000$0.42$22,680.00
1/11/2017Madalena Energy Inc.InsiderSell51,000$0.44$22,440.00
12/2/2016Camber Capital Management LlcMajor ShareholderSell2,500,000$0.32$800,000.00View SEC Filing  
12/14/2015Yossi MaimonCFOBuy10,000$0.78$7,800.00View SEC Filing  
10/19/2015Camber Capital Management LlcMajor ShareholderBuy4,000,423$1.00$4,000,423.00View SEC Filing  
8/15/2013Alfred AkirovDirectorSell112,330$5.05$567,266.50View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Protalix Biotherapeutics (NYSEAMERICAN PLX)


Social Media

Social activity is not available for this stock.



Protalix Biotherapeutics (NYSEAMERICAN PLX) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.